Form 4: MoonLake Immunotherapeutics CEO Sells Shares
Insider Transaction (Form 4)
Da Silva Jorge Santos, Chief Executive Officer and a Director of MoonLake Immunotherapeutics, sold 102,225 shares of common stock on July 9, 2026.
Summary
- Open-market sale: disposed of 33,936 Class A ordinary shares, par value $0.0001 per share at $20.01 ($679,059) on July 9, 2026; holds 2,843,182 after (Direct).
- Open-market sale: disposed of 68,289 Class A ordinary shares, par value $0.0001 per share at $20.02 ($1,367,146) on July 10, 2026; holds 2,774,893 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,046,205 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Da Silva Jorge Santos — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Open-market sale | Class A ordinary shares, par value $0.0001 per share | 33,936 | $20 | $679.1K | 2,843,182 |
| 2026-07-10 | Open-market sale | Class A ordinary shares, par value $0.0001 per share | 68,289 | $20 | $1.4M | 2,774,893 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Open-market sale (33,936 shares) |
| 2026-07-10 | Open-market sale (68,289 shares) |
Keywords
insider transaction, Form 4, MLTX, MoonLake Immunotherapeutics, bearish, Da Silva Jorge Santos
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.